Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
SEC Accession No. 0000315066-25-000856
Filing Date
2025-02-12
Accepted
2025-02-12 09:28:12
Documents
2

Document Format Files

Seq Description Document Type Size
1 primary_doc.html SCHEDULE 13G/A  
1 primary_doc.xml SCHEDULE 13G/A 6838
2 exhibit99.txt EX-99 2959
  Complete submission text file 0000315066-25-000856.txt   11811
Mailing Address 245 SUMMER STREET BOSTON MA 02210
Business Address 245 SUMMER STREET BOSTON MA 02210 6175706339
FMR LLC (Filed by) CIK: 0000315066 (see all company filings)

EIN.: 043532603 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13G/A
SIC: 0000

Mailing Address 53 FRONTAGE ROAD SUITE 220 HAMPTON NJ 08827
Business Address 53 FRONTAGE ROAD SUITE 220 HAMPTON NJ 08827 908-200-7500
Celldex Therapeutics, Inc. (Subject) CIK: 0000744218 (see all company filings)

EIN.: 133191702 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13G/A | Act: 34 | File No.: 005-37761 | Film No.: 25612540
SIC: 2835 In Vitro & In Vivo Diagnostic Substances
(CF Office: 03 Life Sciences)